Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Hepatology Associates Course

    Product not yet rated Contains 10 Component(s) Recorded On: 11/10/2019

    Hepatology Associates Course: Acute on Chronic Liver Failure presented at The Liver Meeting® 2019.

    This comprehensive program will offer the hepatology provider updated information on managing patients with liver disease and/or in the post-transplant setting. Speakers will review new evidence and the latest tools to help providers deliver high-quality patient care, change practice approaches where needed and help improve patient outcomes.

    Amanda J. Chaney
    Angela DeLisle
    Carolyn J. Driscoll
    Victoria Gomez
    Paul Yien Kwo
    Anna S. Lok
    Kaitlyn R. Musto
    Renee S. Pozza

  • Hepatology Associates SIG: Multi-disciplinary Approach in Reducing Readmissions

    Product not yet rated Contains 4 Component(s) Recorded On: 11/10/2019

    Hepatology Associates SIG: Multi-disciplinary Approach in Reducing Readmissions presented at The Liver Meeting® 2019.

    Patient and caregiver education, and transition to care are important aspects for hospital discharge. At this informative program, experts will review multidisciplinary strategies to optimize discharge planning and share innovative models of outpatient care in liver disease, including empowering patients and caregivers, decreasing risk factors and the incidence of hospital readmissions, and reducing costs.

    Amanda J. Chaney
    Summer Collier
    Tiffany E. Kaiser

  • Maintenance of Certification (MOC) Update

    Product not yet rated Contains 6 Component(s) Recorded On: 11/10/2019

    Maintenance of Certification (MOC) Update: Acute on Chronic Liver Failure presented at The Liver Meeting® 2019.

    Discuss the current state of the ABIM Maintenance of Certification (MOC) program for gastroenterologists and transplant hepatologists at this update. Speakers will review the expense, time commitment and relevance of this program’s requirements; current MOC requirements in the program; the means to meet these requirements; progress made in addressing concerns from ABIM diplomats; and alternative pathways to board recertification.

    Ryan M. Kwok
    Paul Mathew
    Heather M. Patton
    Mark W. Russo
    Richard K. Sterling

  • NIH Corner: New Horizons in HCC, NASH and Viral Hepatitis

    Product not yet rated Contains 3 Component(s) Recorded On: 11/10/2019

    NIH Corner: NAFLD Progression: New Horizons in HCC, NASH and Viral Hepatitis presented at The Liver Meeting® 2019.

    Several NIH institutes showcase programs, innovations and opportunities to the AASLD membership at this informative event. Representatives of the NCI, NIDDK, NIAID and NIAAA will present areas of mutual interest to the institute and AASLD membership, including liver cancer, NASH, viral hepatitis and alcohol use disorder. This is a unique opportunity to learn more about interagency collaboration and funding opportunities.

    Jo Ann Rinaudo
    Gary Murray

  • President's Choice Lecture

    Contains 2 Component(s) Recorded On: 11/10/2019

    President's Choice Lecture presented at The Liver Meeting® 2019.

    In the world's poorest nations, the appalling loss of life from easily treated or preventable illnesses represents a moral tragedy. This year's President's Choice Lecture explores potential strategies to correct this inequity, including collaborative partnerships among medical professionals, ways to accurately measure the impact of global disease management efforts and the innovative solutions necessary to accomplish this great task.

    Michael Fried
    Tadataka Yamada

  • Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture: Clinical Vs Science in Personalizing Immunosuppression

    Contains 2 Component(s) Recorded On: 11/10/2019

    Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture: Clinical Vs Science in Personalizing Immunosuppression presented at The Liver Meeting® 2019.

    Immunosuppression in the liver transplant setting includes multiple drugs aimed at predetermined trough levels, adjusted to time after transplantation. Excellent graft and patient survival supports immunosuppression, but there may be significant short- and long-term risks. At this presentation, experts will discuss clinical approaches to immunosuppression in liver transplant patients, including biomarkers used for safe personalization of this process.

    David Mulligan
    Abraham Shaked

  • Value-based Medicine in Hepatology: Defining the Role of Hepatologists in Value-based Care

    Product not yet rated Contains 6 Component(s) Recorded On: 11/10/2019

    Value-based Medicine in Hepatology: Defining the Role of Hepatologists in Value-based Care presented at The Liver Meeting® 2019.

    Value-Based Arrangements are increasingly becoming part of the healthcare landscape. The goal of this program is to educate and empower hepatologists to be valuable contributors to the success of these new arrangements and play an active role in developing and implementing beneficial approaches.

    Meena Bansal
    Ziad Gellad
    Arpan Patel
    Grace Su
    Michael Volk

  • Transplant Surgery Workshop: Liver Transplantation for NASH: Optimizing Outcomes

    Product not yet rated Contains 11 Component(s) Recorded On: 11/09/2019

    Transplant Surgery Workshop: : Liver Transplantation for NASH: Optimizing Outcomes presented at The Liver Meeting® 2019.

    Nonalcoholic steatohepatitis has become a leading indication for liver transplantation in the United States and worldwide. At this symposium, faculty will review pre-transplant evaluation and assessment of comorbid conditions in these patients, early and long-term challenges after transplantation, patterns of recurrence of the disease and potentially preventive strategies.

    Alfred Sidney Barritt IV
    Tayyab Diwan
    Jean Emond
    Ibrahim A. Hanouneh
    Timucin Taner
    Monica A. Tincopa
    Lisa B. VanWagner
    Kymberly Watt

  • 2019 Postgraduate Course: Precision Hepatology in Clinical Practice

    Contains 27 Component(s), Includes Credits Recorded On: 11/09/2019

    AASLD's 2019 Postgraduate Course: Precision Hepatology in Clinical Practice presented at The Liver Meeting® 2019.

    DESCRIPTION
    The practice of Hepatology is largely consultative in nature, whether evaluating outpatients referred for a variety of abnormal liver enzyme findings or diagnosing and managing critically-ill patients within a team of internists, hospitalists, residents, intensivists, and other healthcare providers. On any given day, a hepatologist will be confronted with complex patients and dizzying differential diagnoses to be methodically considered. The aim of this course is to provide insights about state-of-the-art consultative Hepatology attendees that can be applied to daily practice.

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™  
    Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio with an assessment to complete at the end. 
    -Five sessions comprised of three to five video presentations for 15-20 minutes each
    -Course assessment (quiz)
    -Course evaluation to claim continuing education credit

    DIRECTIONS
    Click "Activate/Register" to access the enduring material. Review all section tabs before you begin. Begin video presentations in all sessions. Complete course assessment and evaluation to claim CME and or MOC.
    Time to complete each module: 15-20 minutes

    COPYRIGHT
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org.

    Release date: January 9, 2020
    Expiration date: January 8, 2023

    Upon completion of this activity, participants will be able to:

    Review evidence-based evaluation and management options available for a spectrum of liver diseases, their benefits and risks, and strategies to tailor treatment plans to individual patients.

    Discuss the value of circulating and tissue biomarkers in making rational decisions for optimal patient care.

    Apply information on minimally invasive tests and digital tools to identify biomarkers to the clinical practice of hepatology.

    Hepatologists   

    Gastroenterologists       

    Nurses

    Nurse Practitioners        

    Pharmacists

    Physician Assistants       

    Transplant Coordinators

    Surgeons            

    Fellows/Trainees

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 7.00 AMA PRA Category 1 Credits™
    Maintenance of Certification (MOC): For a maximum of 7.00 MOC Points

    ACCREDITATION AND DESIGNATION STATEMENTS 
    Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 7 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

    HOW TO EARN AND CLAIM MOC POINTS 

                 o    View all video presentation in each session.

                 o    Complete the course evaluation.

                 o    Complete the CME and MOC assessment. You must pass with a score of 70% or higher. Participants have unlimited attempts to earn the passing score.

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to ABIM and ABP by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM or ABP MOC profile.

    **MOC points are available for ABIM or ABP board certified physicians only.**

    Robert Fontana, MD, FAASLD

    Kathryn Fowler, MD

    Scott Friedman, MD, FAASLD

    Fasiha Kanwal, MD, MSHS, FAASLD

    Tom H. Karlsen, MD, PhD

    Verena Keitel, Prof.

    Laura Kulik, MD

    Jennifer C. Lai, MD

    Konstantinos Lazaridis, MD, FAASLD

    Joseph Llovet, MD

    Michael Lucey, MD, FAASLD

    Cara Mack, MD, FAASLD

    Alexander Miethke, MD

    Tushar Patel, MBCHb, FAASLD

    Mary Rinella, MD, FAASLD

    Don Rockey, MD, FAASLD

    Bernd Schnabl, MD, FAASLD

    Gyongyi Szabo, MD, PhD, FAASLD

    Norah Terrault, MD, MPH, FAASLD

    Michael Trauner, MD, FAASLD

    Kymberly Watt, MD

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    This enduring activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Postgraduate Course faculty and the following planning committees: Education Committee, Scientific Program Committee and the Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months.  A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All conflicts of interest are resolved prior to participation.

    Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below:

    FACULTY DISCLOSURES

    Meena Bansal
    AASLD Postgraduate Course Faculty
    Nothing to Disclose

    Ulrich Beuers
    AASLD Postgraduate Course Faculty
    Grant/Research Support: Intercept, Dr.Falk GmbH
    Speaking and Teaching: Intercept, Falk Foundation

    Jorge Bezerra
    AASLD Postgraduate Course Faculty
    Nothing to Disclose

    Raymond Chung
    AASLD Postgraduate Course Faculty
    Advisory Committee or Review Panel: Alnylam
    Grant/Research Support: Boehringer, BMS, Merck, Gilead, Abbvie, Janssen, Roche, Synlogic, Kaleido

    Robert Fontana
    AASLD Postgraduate Course Faculty
    Consulting: Sanofi
    Grant/Research Support: BMS, Gilead, Abbvie

    Kathryn Fowler
    AASLD Postgraduate Course Faculty
    Consulting: 12 Sigma

    Scott Friedman
    AASLD Postgraduate Course Faculty
    Consulting: 3BV Bio, 89Bio, Abide Thearapeutics, Allergan Pharmaceuticals, Avaliv Therapeutics, Axcella Therapeutics, Blade Therapeutics, Bristol Myers Squibb, Contravir, CymaBay, DeuteRx, Enanta Pharmaceuticals, Escient Therapeutics, Exalenz Biosciences, Forbion, Fractyl Bioscience, Five Prime Therapeutics , Galmed, Genfit, Gemphire, Glycotest, Heparegenix, Janssen Pharmaceuticals, Jecure Therapeutics, Kintai, Madrigal Pharmaceuticals, Metacrine, Mistral, Morphic Rock Therapeutics, NGM Pharmaceuticals, Nimbus Therapeutics, Nitto Corp., North Sea Therapeutics, Novartis, Novo Nordisk, Pfizer Pharmaceuticals, Salix, Scholar Rock, Seal Rock Therapeutics, Second Genome, Surrozen, Symbic Bio, Takeda Pharmaceuticals, Viking Therapeutics
    Grant/Research Support: 3VBio, Enanta, Scholar Rock, Gemphire, North Sea Therapeutics

    Fasiha Kanwal
    AASLD Postgraduate Course Faculty
    Grant/Research Support: Merck, Gilead

    Tom Karlsen
    AASLD Postgraduate Course Faculty
    Nothing to Disclose

    Andrew Keaveny
    AASLD Postgraduate Course Faculty
    Grant/Research Support: HepQuant LLC, Conatus Pharmaceuticals, Mallinckrodt Medical Inc
    Independent Contractor: UpToDate Inc
    Speaking and Teaching: Medscape Inc.

    Verena Keitel
    AASLD Postgraduate Course Faculty
    Speaking and Teaching: Abbvie, Falk Foundation

    Laura Kulik
    AASLD Postgraduate Course Faculty
    Nothing to Disclose 

    Jennifer C. Lai
    AASLD Postgraduate Course Faculty
    Consulting: Axcella Health, Inc

    Konstantinos Lazaridis
    AASLD Postgraduate Course Faculty
    Nothing to Disclose

    Josep Llovet
    AASLD Postgraduate Course Faculty
    Consulting: Ipsen, Merck, Bristol Myers Squibb, Eisai Inc, Bayer HealthCare Pharmaceuticals, Midatech Ltd, Navigant, Fortress Biotech Inc, Spring Bank Pharmaceutical, Glycotest, Leerink Swann LLC, Eli Lilly, Celsion Corporation, Exelixis, Nucleix, Can-Fite Biopharma
    Grant/Research Support: Bristol Myers Squibb, Eisai Inc, Bayer Healthcare Pharmaceuticals, Ipsen, Blueprint Incyte

    Rohit Loomba
    AASLD Postgraduate Course Faculty
    Consulting: Bird Rock Bio, Merck & Co., NGM, Cymabay, Metacrine, Ionis, Glympse Bio, Pfizer, Eli Lilly and Company
    Grant/Research Support: Intercept, NGM Bio, Novo Nordisk, Novartis, Prometheus, Janssen, Cirius Therapeutics, Gilead, Eli Lilly

    Michael Lucey
    AASLD Postgraduate Course Faculty
    Grant/Research Support: NIAAA, Pharma-solutions, Gilead, Abbvie

    Cara Mack
    AASLD Postgraduate Course Faculty
    Consulting: albireo

    Alexander Miethke
    AASLD Postgraduate Course Faculty
    Consulting: Mirum Inc, Metacrine Inc
    Lopa Mishra
    Research Grants: NIH

    Vicky Ng
    AASLD Postgraduate Course Faculty
    Advisory Committee or Review Panel: Albireo

    Tushar Patel
    AASLD Postgraduate Course Faculty
    Disclosures were not provided

    Nancy Reau
    AASLD Postgraduate Course Faculty
    Advisory Committee or Review Panel: Gilead, intercept, Merck, abbVie
    Consulting: BMS
    Grant/Research Support: GenFit

    Mary Rinella
    AASLD Postgraduate Course Faculty
    Consulting: NGM Biopharmaceuticals, Genfit, Gilead, Intercept, Novartis, Metacrine, Bristol Meyers Squibb, Gelesis, Fractyl, Pfizer, Madrigal, Enanta, Echosens, Merck, Viking
    Grant/Research Support: Gilead, Conatus, NGM, Cirius, Enanta, Intercept, Novartis, Allergan

    Don Rockey
    AASLD Postgraduate Course Faculty
    Grant/Research Support: Terlipressin, Intercept Pharm, Mallinckrodt Pharm, Genfit Reg, INC, Aflmmune, Salix, Cumberland Pharm, NIH/NIDDK, Ironwood Pharm, Gilead Services, Conatus Pharm

    Bernd Schnabl
    AASLD Postgraduate Course Faculty
    Consulting: Ferring Pharmaceuticals, Patara Pharmaceuticals, Intercept Pharmaceuticals
    Grant/Research Support: CymaBay Therapeutics, Synlogic Operating Company

    Ronald Sokol
    AASLD Postgraduate Course Faculty
    Consulting: Alexion, Retrophin, Shire, Albireo

    Gyongyi Szabo
    AASLD Postgraduate Course Faculty
    Advisory Committee or Review Panel: UPENN Digestive Disease Center, Yale Liver Center, BWH-DSMB, VCU MSTP, NIH ExRNA Program, UCLA Liver Center, Galaxy Project, Nature Gastro & Hepatology, University of Pittsburgh MSTP Program, University of Louisville Alcohol Center, Upstate Medical Univ. Syracuse NY, Carlos Foundation- Mayo Clinic, MICA

    Norah Terrault
    AASLD Postgraduate Course Faculty
    Grant/Research Support: Gilead Sciences

    Michael Trauner
    AASLD Postgraduate Course Faculty
    Consulting: Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus
    Grant/Research Support: Albireo, Cymabay, Falk, Gilead, Intercept, MSD, Takeda
    Speaking and Teaching: Falk, Gilead, Intercept, MSD, Roche

    Kymberly Watt
    AASLD Postgraduate Course Faculty
    Stock Shareholder: Arbutus, Madrigal, Viking, BMS

    Rebecca Wells
    AASLD Postgraduate Course Faculty
    Nothing to Disclose

    PLANNER DISCLOSURES

    Veeral Ajmera 
    Annual Meeting Education Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Luminist Incorporated

    Gyorgy Baffy 
    Annual Meeting Education Committee
    Nothing to Disclose 

    Meena Bansal
    Governing Board and Scientific Program Committee
    Data Safety Monitoring Board for Industry or Commercial Enterprise: TREAT Consortium (NIH; not commercial entity)                                                                                                                                           
    Research Grants: Paid to institution:  NIH R01                                                                                                         
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Kinetix Group; Boehringer-Ingelheim 

    Ramon Bataller
    Annual Meeting Education Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Echosens

    Alex Befeler 
    Scientific Program Committee
    Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: Amgen
    long term stockholder (independently managed by CPA), Gilead long term stockholder (independently managed by CPA)                                                                                                                                       
    Research Grants: mallinckrodt, Salix, Sillajen 

    Jorge Bezerra 
    Governing Board and Scientific Program Committee
    Research Grants: Gilead; Shyer

    Andres Cardenas 
    Annual Meeting Education Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Boston Scientific Corp Scientific                                                                   
    Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Mallinckrodt Pharmaceuticals - Consultant

    Raymond Chung 
    Governing Board and Scientific Program Committee
    Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB Alnylam                     
    Research Grants: Gilead Sciences. Abbvie, Boehringer Ingelheim, BMS, Roche, Janssen, Merck, Kaleido, Synlogic

    Virginia Clark 
    Annual Meeting Education Committee
    Research Grants: Genfit

    James Daniel 
    Annual Meeting Education Committee
    Research Grants: Gilead and Hoffmann- La Roche

    Laurie DeLeve 
    Annual Meeting Education Committee and Governing Board
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Pfizer, Daiichi Sankyo, Boehringer-Ingelheim                                                     
    Intellectual Property Rights (Patents, Royalties, Licensing fees): 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment, COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES -(sole inventor) - Applicant: University of Southern California, GBC ref.: 6177.132445PCT

    Michael Fried 
    Governing Board and Scientific Program Committee
    Research Grants: AbbVie, BMS, Gilead, Merck, National Institutes of Health
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)                                        Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: TARGET PharmaSolutions (Maintained in independent blind trust)

    Patrick Horne 
    Annual Meeting Education Committee and Scientific Program Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Abbvie, Gilead, Intercept

    Sofia Jakab 
    Annual Meeting Education Committee
    Nothing to Disclose 

    Michael Kriss 
    Annual Meeting Education Committee
    Nothing to Disclose

    Laura Kulik
    Annual Meeting Education Committee
    Nothing to Disclose 

    John Lake 
    Governing Board
    Research Grants: CymbaBay, Data Safety                                                                                                           
    Monitoring Board for Industry or Commercial Enterprise: Intercept DSMB                                             
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: SRTR

    Bruce Luxon 
    Governing Board
    Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB for Baxalta; DSMB for Sparks (for treatment of Hemophilia)                                                                                                               
    Leadership in related society: Board, Committee, Journal: Research Committee member for the ACG

    John Magee
    Scientific Program Committee
    Nothing to Disclose

    Mitchell Mah'moud 
    Annual Meeting Education Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Chronic Liver a Disease Foundation

    Harmeet Malhi
    Scientific Program Committee
    Research Grants: NIH R01 NIH U01

    Lopa Mishra 
    Governing Board
    Research Grants: NIH

    David Mulligan 
    Governing Board
    Nothing to Disclose

    Mary Panther  
    Annual Meeting Education Committee
    Nothing to Disclose 

    K. Gautham Reddy 
    Scientific Program Committee
    Research Grants: CymaBay; Genfit; Intercept; Target PharmaSolutions; Arrowhead; Gilead; Durect;
    Commercial Speaker's Bureau: Intercept, Dova                                                                                           
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

    Hemant Shah 
    Annual Meeting Education Committee
    Advisory Board: Abbvie, Gilead, Intercept, Lupin, Merck, Pendopharm

    Ronald Sokol 
    Governing Board
    Research Grants: Paid to institution: Lumena/Shire; Albireo
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Alexion; Albireo; Retrophin; Shire; Mirum

    Richard Sterling  
    Annual Meeting Education Committee
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Gilead, Roche, AbbVie, Baxter, Pfizer, Merck within the last 12 months.  
    I have had no activity with Gilead, AbbVie, and Merck in the last 6 months in anticipation of the Non-Invasive Guidelines paper that is expected to start 2018.
    Research Grants: Gilead, Roche, True Health, AbbVie, Abbott

    Grace Su 
    Annual Meeting Education Committee and Scientific Program Committee
    Intellectual Property Rights (Patents, Royalties, Licensing fees): Patent on Image analysis and Morphomic
    Leadership in related society: Board, Committee  Journal: Member, Clinical Guidelines Committee, AGA; Company Employee, Officer, Director : My husband and son have equity interest in Applied Morphomics and Prenovo.

    Norah Terrault
    Governing Board
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Advisory Committees or Review Panels: Dova Pharmaceuticals       
    Research Grants: Grant/Research Support: AbbVie, Gilead, BMS, Merck 

    Jason Vanatta 
    Annual Meeting Education Committee
    Nothing to Disclose 

    Kymberly Watt
    Scientific Program Committee                                                                                               
    Expert testimony: Intercept - site- PI
    Gilead - site PI, co-I
    Conatus - site co-I
    Novartis - previous site PI, co author study subanalysis
    Pfizer- site co-I (all multicenter study related)                                                                                                   
    Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: BMS; Arbutus; Madrigal; Viking

    Steven Weinman 
    Annual Meeting Education Committee
    Nothing to Disclose

    Maureen Whitsett 
    Annual Meeting Education Committee
    Nothing to Disclose 

    AASLD STAFF DISCLOSURES

    Greg Bologna 
    AASLD Staff 
    Nothing to Disclose

    Dominique Clayton
    AASLD Staff
    Nothing to Disclose

    Amy D'Amato 
    AASLD Staff
    Nothing to Disclose

    Julie Deal 
    AASLD Staff 
    Nothing to Disclose

    Katie Duggan
    AASLD Staff
    Nothing to Disclose

    Stephanie Graham
    AASLD Staff 
    Nothing to Disclose

    Stephanie Grimsby 
    AASLD Staff
    Nothing to Disclose

    Jessica Jessop
    AASLD Staff 
    Nothing to Disclose

    Janeil C. Klett 
    AASLD Staff 
    Nothing to Disclose

    John Lingerfelt
    AASLD Staff 
    Nothing to Disclose

    Julia Merrill
    AASLD Staff 
    Nothing to Disclose

    Bette Anne Preston
    AASLD Staff 
    Nothing to Disclose

    Diane Perrino 
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • AASLD/NASPGHAN Pediatric Symposium: New Endoscopic Frontiers in Liver Disease

    Contains 5 Component(s) Recorded On: 11/08/2019

    AASLD/NASPGHAN Pediatric Symposium: New Endoscopic Frontiers in Liver Disease presented at The Liver Meeting® 2019.

    At this symposium, experts on pediatric acute liver failure (PALF) will review the role of inflammation in etiopathogenesis of common comorbidities and discuss emerging topics in pediatric acute-on-chronic liver failure and extrahepatic support strategies. They will discuss the complexity of medical decision making in PALF and review indications for liver transplant in these patients.

    Edward Behrens
    Anil Dhawan
    James E. Squires
    Janis M. Stoll